Matched‐pair and propensity score comparisons of outcomes of patients with clinical stage I non–small cell lung cancer treated with resection or stereotactic radiosurgery

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98996/1/cncr28100.pd

Comprehensive Cancer Control Branch Program evaluation toolkit

The Comprehensive Cancer Control Branch (CCCB) is part of the Centers for Disease Control and Prevention's (CDC's) Division of Cancer Prevention and Control (DCPC). CCCB developed this toolkit to help funded programs meet the evaluation requirements established for their cooperative agreements. This toolkit provides general guidance on evaluation principles and techniques, as well as practical templates and tools; therefore, grantees can continue to use the toolkit to support their evaluation efforts even as the program evolves and priorities change.Toolkit overview -- 1. Evaluation primer -- 2. How to evaluate your CCC program -- 3. Glossary of evaluation terms -- 4. For further study -- 5. Toolkit evaluation: we want your feedback -- 6. References -- Appendix A. Key contacts and toolkit development -- Appendix B. Evaluation plan template -- Appendix C. Sample logic model"June 2010."Also available via the World Wide Web as an Acrobat .pdf file (3.79 MB, 81 p.).Includes bibliographical references (p. 65)

Colorectal cancer

"Colorectal cancer is the #2 cancer killer in the US among cancers that affect both men and women. But it doesn't have to be. Screening can find precancerous polyps (abnormal growths) so they can be removed before they turn into cancer. Screening can also find colorectal cancer early when it is easiest to treat. A new CDC report says that rates of new cases and deaths of colorectal cancer are decreasing and more adults are being screened. Between 2003 and 2007, approximately 66,000 colorectal cancer cases were prevented and 32,000 lives were saved compared to 2002. Half of these prevented cases and deaths were due to screening." -p. 1Fact sheet released by the Centers for Disease Control and Prevention's Office of Surveillance, Epidemiology and Laboratory Services (OSELS) in association with: Vital signs: colorectal cancer screening, incidence, and mortality -- United States, 2002-2010 published: MMWR. Morbidity and mortality weekly report ; v. 60, early release, July 5, 2011, p. 1-6."223580-B.""April 2011.""Publication date: 07/05/2011."Title from title screen (viewed July 5, 2011).Mode of access: World Wide WebText document (PDF)

Preventing and controlling cancer: the nation's second leading cause of death

Describes CDC's Division of Cancer Prevention and Control (DCPC) cancer prevention and control activities."January 2008."Mode of access: World Wide web.Text (PDF), graphic

Colorectal cancer

"Binge drinking (men drinking 5 or more alcoholic drinks within a short period of time or women drinking 4 or more drinks during a short period of time) is a dangerous behavior for all ages. Drinking too much, including binge drinking, causes more than 79,000 deaths in the US each year and is a leading preventable cause of death. Binge drinking has not been well-recognized as a public health problem. More than 15% of US adults report binge drinking. It is most common in men, adults in the 18-34 age range, and people with household incomes of $75,000 or more. This is a community issue, not just an individual issue. This CDC report points out how common binge drinking is and what can be done about it." -p. 1Fact sheet released by the Centers for Disease Control and Prevention's Office of Surveillance, Epidemiology and Laboratory Services (OSELS) in association with: Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008, published: MMWR Morb Mortal Wkly Rep. 2010 Jul 9;59(26):808-12; and: Vital signs: breast cancer screening among women aged 50-74 years - United States, 2008, published: MMWR Morb Mortal Wkly Rep. 2010 Jul 9;59(26):813-6."July 2010.""Publication date: 07/06/2010."Title from title screen (viewed November 16, 2010).Colrectal cancer: -- Problem -- Who's at risk? -- U.S. states info -- -- Breast cancer: -- Problem -- Who's at risk? -- U.S. states infoMode of access: World Wide WebText document (PDF)

Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer

BACKGROUND: Receipt of chemotherapy at the end of life (EOL) is considered an indicator of poor quality of care for medical oncology. The objective of this study was to characterize the use of radiotherapy (RT) in patients with nonsmall cell lung cancer (NSCLC) during the same period. METHODS: Treatment characteristics of patients with incurable NSCLC who received RT at the EOL, defined as within 14 days of death, were analyzed from the National Comprehensive Cancer Network NSCLC Outcomes Database. RESULTS: Among 1098 patients who died, 10% had received EOL RT. Patients who did and did not receive EOL RT were similar in terms of sex, race, comorbid disease, and Eastern Cooperative Oncology Group performance status. On multivariable logistic regression analysis, independent predictors of receiving EOL RT included stage IV disease (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.09‐3.83) or multiorgan involvement (OR, 1.75; 95% CI, 1.08‐2.84) at diagnosis, age <65 years at diagnosis (OR, 1.85; 95% CI, 1.21‐2.83), and treating institution (OR, 1.24‐5.94; P = .02). Nearly 50% of EOL RT recipients did not complete it, most commonly because of death or patient preference. CONCLUSIONS: In general, EOL RT was received infrequently, was delivered more commonly to younger patients with more advanced disease, and often was not completed as planned. There also was considerable variation in its use among National Comprehensive Cancer Network institutions. Next steps include expanding this research to other cancers and settings and investigating the clinical benefit of such treatment. Cancer 2012. © 2012 American Cancer Society. The authors characterize the use of radiotherapy in patients with incurable nonsmall cell lung cancer during their last 14 days of life and observe that its use is infrequent, it is delivered more commonly to younger patients with more advanced disease, and it is completed as planned only approximately half of the time. There is also significant institutional variation in its use; thus, future investigations should aim to expand this research to other cancers and settings and to investigate the clinical benefit of such treatment.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/93552/1/27401_ftp.pd

Trends in esophageal cancer incidence by histology, United States, 1998–2003

Esophageal adenocarcinoma rates may be increasing, whereas, squamous cell carcinoma rates appear to be decreasing in the United States. Previous population-based research on esophageal cancer has only covered up to 68% of the country. Additional, updated research on a larger percentage of the country is needed to describe racial, ethnic and regional trends in histologic subtypes of esophageal cancer. Invasive esophageal cancer cases diagnosed between 1998 and 2003 (n = 65,926), collected by the National Program of Cancer Registries or the Surveillance, Epidemiology, and End Results program, were included. These data cover 83% of the US population. Esophageal squamous cell carcinoma incidence fell by 3.6%/year, whereas esophageal adenocarcinoma increased by 2.1%/year. Squamous cell carcinoma rates decreased among both sexes in most racial or ethnic groups, whereas adenocarcinoma rates increased primarily among white or non-Hispanic men. Except for white or non-Hispanic men, squamous cell carcinoma rates were similar to, or greater than, adenocarcinoma rates for men and women of all other races and ethnicities. The largest decrease in squamous cell carcinoma rates occurred in the West census region, which also exhibited no increase in adenocarcinoma rates. The rate of regional and distant-staged adenocarcinomas increased, while rates for local-staged adenocarcinoma remained stable. This is the first article to characterize esophageal cancer trends using data covering the majority of the US. Substantial racial, ethnic and regional variation in esophageal cancer is present in the US. Our work may inform interventions related to tobacco and alcohol use, and overweight/obesity prevention, and provide avenues for further research

Comparison of Hospital Charge Prediction Models for Colorectal Cancer Patients: Neural Network vs. Decision Tree Models

Analysis and prediction of the care charges related to colorectal cancer in Korea are important for the allocation of medical resources and the establishment of medical policies because the incidence and the hospital charges for colorectal cancer are rapidly increasing. But the previous studies based on statistical analysis to predictthe hospital charges for patients did not show satisfactory results. Recently, data mining emerges as a new technique to extract knowledge from the huge and diverse medical data. Thus, we built models using data mining techniques to predict hospital charge for the patients. A total of 1,022 admission records with 154 variables of 492 patients were used to build prediction models who had been treated from 1999 to 2002 in the Kyung Hee University Hospital. We built an artificial neural network (ANN) model and a classification and regression tree (CART) model, and compared their prediction accuracy. Linear correlation coefficients were high in both models and the mean absolute errors were similar. But ANN models showed a better linear correlation than CART model (0.813 vs. 0.713 for the hospital charge paid by insurance and 0.746 vs. 0.720 for the hospital charge paid by patients). We suggest that ANN model has a better performance to predict charges of colorectal cancer patients